Sandu Pharmaceuticals Limited (SANDUPHQ.BO)
INR 56.0
(-0.37%)
INR 56.0
(-0.37%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 8.56 Million | 2.21 Million | 9.48 Million | 75.9 Million | 62.02 Million | 37.41 Million |
| Net Income | 14.61 Million | 22.16 Million | 23.16 Million | 16.8 Million | 9.19 Million | 10.17 Million |
| Depreciation & Amortization | 5.83 Million | 5.16 Million | 5.3 Million | 5.56 Million | 5.52 Million | 6.35 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -12.24 Million | -17.74 Million | -11.25 Million | 57.45 Million | 44.66 Million | 13.51 Million |
| Other non-cash items | 34.52 Million | -7.38 Million | -7.73 Million | -3.92 Million | 2.64 Million | 7.36 Million |
| Investing Cash Flow | -14.66 Million | 5.36 Million | -54.72 Million | -55.76 Million | -3.66 Million | -1 Million |
| Investments in PPE | -14.25 Million | -10.68 Million | -8.41 Million | -1.27 Million | -1.12 Million | -1.08 Million |
| Acquisitions | - | 1.58 Million | 823 Thousand | 1.93 Million | - | - |
| Investment purchases | -10 Million | -4 Million | -105.14 Million | -68.07 Million | -2.76 Million | - |
| Sales/Maturities of investments | 10.18 Million | 18.47 Million | 58 Million | 11.64 Million | - | - |
| Other Investing Activities | -595 Thousand | 1000.00 | 1000.00 | -1000.00 | 217.2 Thousand | 87.3 Thousand |
| Financing Cash Flow | -6.61 Million | 5.79 Million | 9.34 Million | 12.97 Million | -53.59 Million | -42.59 Million |
| Debt repayment | -633 Thousand | - | -193 Thousand | -12.25 Million | -49.24 Million | -32.47 Million |
| Dividends payments | -7.24 Million | -6.6 Million | -3.16 Million | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 13.19 Million | 13.8 Million | 17.38 Million | - | - |
| Other Financing Activities | 633 Thousand | -796 Thousand | -1.1 Million | 7.85 Million | -4.34 Million | -10.11 Million |
| Accounts receivables | -1.18 Million | -8.38 Million | 13.16 Million | -7.91 Million | 1.14 Million | 18.98 Million |
| Accounts payables | -42.05 Million | 15.79 Million | 1.47 Million | 9.11 Million | 15.25 Million | 12.11 Million |
| Inventory | 20.75 Million | -30.53 Million | -1.34 Million | 32.23 Million | -11.06 Million | -18.15 Million |
| Other working capital | 10.25 Million | 5.37 Million | -24.55 Million | 24.01 Million | 39.33 Million | 562.69 Thousand |
| Cash at beginning of period | 22.75 Million | 9.38 Million | 45.27 Million | 12.16 Million | 7.4 Million | 14.07 Million |
| Cash at end of period | 12.06 Million | 22.75 Million | 9.38 Million | 45.27 Million | 12.16 Million | 7.89 Million |
| Capital Expenditure | -14.25 Million | -10.68 Million | -8.41 Million | -1.27 Million | -1.12 Million | -1.08 Million |
| Effect of forex changes on cash | - | 1000.00 | - | - | -2.00 | -6.00 |
| Net cash flow / Change in cash | -10.69 Million | 13.37 Million | -35.89 Million | 33.11 Million | 4.75 Million | -6.18 Million |
| Free Cash Flow | -5.68 Million | -8.47 Million | 1.07 Million | 74.63 Million | 60.89 Million | 36.32 Million |
| Breakdown | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY | 2022 Q4 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 14.61 Million | 2.06 Million | 5.5 Million | 1.09 Million | 22.16 Million | 2.71 Million |
| Depreciation & Amortization | 5.83 Million | 1.41 Million | 1.32 Million | 1.22 Million | 5.16 Million | 1.34 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -12.24 Million | - | - | - | -17.74 Million | - |
| Other non-cash items | 34.52 Million | -647 Thousand | -1.32 Million | -1.22 Million | -7.38 Million | -1.34 Million |
| Investing Cash Flow | -14.66 Million | - | - | - | 5.36 Million | - |
| Investments in PPE | -14.25 Million | - | - | - | -10.68 Million | - |
| Acquisitions | - | - | - | - | 1.58 Million | - |
| Investment purchases | -10 Million | - | - | - | -4 Million | - |
| Sales/Maturities of investments | 10.18 Million | - | - | - | 18.47 Million | - |
| Other Investing Activities | -595 Thousand | - | - | - | 1000.00 | - |
| Financing Cash Flow | -6.61 Million | - | - | - | 5.79 Million | - |
| Debt repayment | -633 Thousand | - | - | - | - | - |
| Dividends payments | -7.24 Million | - | - | - | -6.6 Million | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | 13.19 Million | - |
| Other Financing Activities | 633 Thousand | - | - | - | -796 Thousand | - |
| Accounts receivables | -1.18 Million | - | - | - | -8.38 Million | - |
| Accounts payables | -42.05 Million | - | - | - | 15.79 Million | - |
| Inventory | 20.75 Million | - | - | - | -30.53 Million | - |
| Other working capital | 10.25 Million | - | - | - | 5.37 Million | - |
| Cash at beginning of period | 22.75 Million | 15.54 Million | 10.03 Million | 22.75 Million | 9.38 Million | 20.03 Million |
| Cash at end of period | 12.06 Million | 18.37 Million | 15.54 Million | 1.09 Million | 22.75 Million | 22.75 Million |
| Capital Expenditure | -14.25 Million | - | - | - | -10.68 Million | - |
| Effect of forex changes on cash | - | - | - | - | 1000.00 | - |
| Net cash flow / Change in cash | -10.69 Million | 2.83 Million | 5.5 Million | -21.66 Million | 13.37 Million | 2.71 Million |
| Free Cash Flow | -5.68 Million | 2.83 Million | 5.5 Million | 1.09 Million | -8.47 Million | 2.71 Million |
PEBB
4921
3591
ARZTY
AHLEAST
601069